GW Pharmaceuticals Stock Today

<div class='circular--portrait' style='background:#FF6600;color: #f7f7f7;font-size:4em;padding-top: 25px;;'>GP</div>
GW Pharmaceuticals is trading at 139.54 as of the 15th of July 2020. This is 5.56 percent increase since the beginning of the trading day. The stock's open price was 132.19. GW Pharmaceuticals has a very small chance of experiencing financial distress in the next few years and had a very solid performance during the last 30 days. Equity ratings for GW Pharmaceuticals Plc are calculated daily based on the scoring framework. The performance scores are derived for the period starting the 16th of April 2020 and ending today, the 15th of July 2020. Click here to learn more.
Analyze Filter   Check how we calculate scores

   Performance
17 100 

GW Pharmaceuticals Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom. GW Pharmaceuticals operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 901 people. more on GW Pharmaceuticals
GW Pharmaceuticals Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
GW Pharmaceuticals Plc SEC Filings
GW Pharmaceuticals SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameGW Pharmaceuticals Plc
CEO, DirectorJustin GoverView All
Thematic Classification
Currently Active Investing Idea
  Marijuana
View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering GW Pharmaceuticals Plc. The GW Pharmaceuticals consensus assessment is calculated by taking the average estimates from all of the analysts covering GW Pharmaceuticals
Piotroski F Score
Academic score (developed by Joseph Piotroski in 2002) to determine the current strength of GW Pharmaceuticals Plc financial position. Scores of 8 and 9 are usually clasified strong value stocks whereas scores of 2 or below are considered weak value stocks.
 2 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares410.7 M427.3 M
Sufficiently Down
Increasing
Slightly volatile
Weighted Average Shares Diluted410.7 M427.3 M
Sufficiently Down
Increasing
Slightly volatile
Net Cash Flow from Operations(119.9 M)(111.1 M)
Significantly Down
Decreasing
Stable
Total Assets884.4 MB
Fairly Down
Increasing
Slightly volatile
Total Liabilities151.2 M179.6 M
Fairly Down
Increasing
Slightly volatile
Current Assets704.2 M804.6 M
Fairly Down
Increasing
Slightly volatile
Current Liabilities113.8 M135.2 M
Fairly Down
Increasing
Slightly volatile
Total Debt33.8 M31.3 M
Significantly Up
Increasing
Slightly volatile
Return on Average Assets(0.0136)(0.0126)
Significantly Down
Increasing
Slightly volatile
Gross Margin0.931.05
Fairly Down
Increasing
Slightly volatile
Asset Turnover0.340.43
Significantly Down
Increasing
Slightly volatile
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of GW Pharmaceuticals available fundamental, technical, and predictive indicators. Current horizon is 30 days (very short) - details
Strong BuyUndervalued
Financial Strength
GW Pharmaceuticals financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to GW Pharmaceuticals success along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
  Operating Cash Flow
GW Pharmaceuticals Plc (GWPH) is traded on BATS Exchange in USA. It is located in Sovereign House Vision Park, Chivers Way Histon, Cambridge CB24 9BZ, United Kingdom and employs 901 people. GW Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 4.04 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate GW Pharmaceuticals's market, we take the total number of its shares issued and multiply it by GW Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. GW Pharmaceuticals Plc conducts business under Healthcare sector and is part of Drug Manufacturers?General industry. The entity has 31.08 M outstanding shares of which 4.48 M shares are currently shorted by private and institutional investors with about 13.81 trading days to cover. GW Pharmaceuticals Plc currently holds about 500.94 M in cash with (83.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.12.
Check GW Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

GW Pharmaceuticals Stock Price Odds Analysis

Odds Down 139.54HorizonTargetOdds Up 139.54
97.01%30 days
 139.54 
2.97%
Based on a normal probability distribution, the odds of GW Pharmaceuticals to move above the current price in 30 days from now is roughly 2.97 (This GW Pharmaceuticals Plc probability density function shows the probability of GW Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

GW Pharmaceuticals Income Statement Over Time

GW Pharmaceuticals Plc Income Statement is one of the three primary financial statements used for reporting GW Pharmaceuticals's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of GW Pharmaceuticals Plc revenue and expense. GW Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period. GW Pharmaceuticals Gross Profit is most likely to increase significantly in the upcoming years. The last year's value of Gross Profit was reported at 326.75 Million. The current Revenues is estimated to increase to about 386.3 M, while Consolidated Income is projected to decrease to (11.2 M). View More Fundamentals

GW Pharmaceuticals Stock Against Markets

Did you try this?

Run Portfolio Diagnostics Now

   

Portfolio Diagnostics

Use generated alerts and portfolio events aggregator to diagnose current holdings
All  Next Launch Module

GW Pharmaceuticals Corporate Filings

GW Pharmaceuticals SEC Reporting

Submission of Matters to a Vote of Security Holders
View
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
Unclassified Corporate Event
View

GW Pharmaceuticals Corporate Directors

William Waldegrave Non-Executive Independent Director
Christopher Tovey COO, Executive Director
Thomas Lynch Non-Executive Independent Director
Please check Risk vs Return Analysis. Please also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page